Chemomab Therapeutics (CMMB) Competitors $1.15 -0.02 (-1.71%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.15 0.00 (0.00%) As of 07/15/2025 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. XBIT, IVVD, OKYO, ADAG, ORMP, CABA, ELUT, MGX, EPIX, and EXOZShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include XBiotech (XBIT), Invivyd (IVVD), OKYO Pharma (OKYO), Adagene (ADAG), Oramed Pharmaceuticals (ORMP), Cabaletta Bio (CABA), Elutia (ELUT), Metagenomi (MGX), ESSA Pharma (EPIX), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Its Competitors XBiotech Invivyd OKYO Pharma Adagene Oramed Pharmaceuticals Cabaletta Bio Elutia Metagenomi ESSA Pharma eXoZymes Chemomab Therapeutics (NASDAQ:CMMB) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends. Which has stronger valuation and earnings, CMMB or XBIT? XBiotech is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$13.94M-$0.76-1.51XBiotechN/AN/A-$38.53M-$1.29-2.13 Which has more volatility and risk, CMMB or XBIT? Chemomab Therapeutics has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Does the media prefer CMMB or XBIT? In the previous week, XBiotech had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for XBiotech and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.89 beat XBiotech's score of 1.52 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Chemomab Therapeutics Very Positive XBiotech Very Positive Do analysts recommend CMMB or XBIT? Chemomab Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 639.13%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Chemomab Therapeutics is more favorable than XBiotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00XBiotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CMMB or XBIT more profitable? XBiotech's return on equity of -21.14% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -106.70% -82.18% XBiotech N/A -21.14%-19.55% Do insiders & institutionals have more ownership in CMMB or XBIT? 46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryChemomab Therapeutics beats XBiotech on 7 of the 13 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.06M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-1.5120.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book1.607.568.145.54Net Income-$13.94M-$55.11M$3.24B$257.73M7 Day Performance-1.71%3.81%0.18%-0.08%1 Month Performance-6.50%11.60%5.96%8.09%1 Year Performance2.68%-2.11%26.24%13.02% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics2.7693 of 5 stars$1.15-1.7%$8.50+639.1%+5.5%$22.06MN/A-1.5120Gap UpXBITXBiotech1.9166 of 5 stars$2.89+2.1%N/A-56.3%$88.12M$4.01M-2.24100News CoverageIVVDInvivyd3.4275 of 5 stars$0.73-1.2%$5.85+701.4%-47.1%$87.57M$36.69M-0.61100OKYOOKYO Pharma3.3213 of 5 stars$2.58-8.2%$7.00+171.3%+73.0%$87.30MN/A0.007Gap UpADAGAdagene2.4974 of 5 stars$1.85-3.1%$8.00+332.4%-30.4%$87.15M$100K0.00260News CoverageUpcoming EarningsGap UpORMPOramed Pharmaceuticals1.0297 of 5 stars$2.13-0.5%N/A-17.4%$87.01M$1.34M-4.8410Positive NewsCABACabaletta Bio2.7495 of 5 stars$1.69-2.9%$14.43+753.8%-79.1%$85.75MN/A-0.6750News CoverageELUTElutia3.6776 of 5 stars$2.05-14.2%$8.00+290.2%-54.6%$84.30M$24.38M-1.06180Positive NewsMGXMetagenomi2.8954 of 5 stars$2.25+3.2%$13.00+477.8%-57.8%$84.11M$52.29M-1.07236Gap UpEPIXESSA Pharma1.0674 of 5 stars$1.86+8.8%$2.00+7.5%-66.7%$82.57MN/A-2.9550High Trading VolumeEXOZeXoZymesN/A$9.81flatN/AN/A$82.11M$70K0.0029Positive NewsGap Down Related Companies and Tools Related Companies XBIT Competitors IVVD Competitors OKYO Competitors ADAG Competitors ORMP Competitors CABA Competitors ELUT Competitors MGX Competitors EPIX Competitors EXOZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
